Key insights
- Abbott Labs director Daniel Starks purchased $926,537 in ABT shares near its 52-week low, signaling potential undervaluation. The purchase was supplemented by restricted stock unit and stock option grants. While Q1 sales aligned with expectations, diabetes and respiratory segments faced challenges. The director's purchase, coupled with a high dividend yield, provides a mildly bullish signal.
Daniel J. Starks, a director at Abbott Laboratories (NYSE:ABT), purchased 10,000 common shares of the company’s stock on April 27, 2026. The transactions totaled $926,537. The shares were acquired at a weighted average price of $92.6537 per share, with individual prices ranging from $92.43 to $93.04. The timing is notable as Abbott currently trades near its 52-week low of $90.72, down ~24% year-to-date, though InvestingPro analysis suggests the $163 billion healthcare giant appears undervalued at current levels.
Separately, on April 24, 2026, Mr. Starks received a grant of 2,286 common shares as a restricted stock unit award under the Abbott Laboratories 2026 Incentive Stock Program. This award was recorded at a price of $0 per share and will be paid out, on a one-to-one basis, in Abbott common shares upon the earlier of his separation from service, death, or a change in control, as defined by the program.
Also on April 24, 2026, Mr. Starks was granted 7,105 stock options under the same Incentive Stock Program. These options have an exercise price of $91.86 per share and an expiration date of April 23, 2036. Abbott has maintained dividend payments for 56 consecutive years with a current yield of 2.68%—one of 11+ InvestingPro Tips available for deeper analysis, alongside a comprehensive Pro Research Report.
Following these transactions, Mr. Starks directly holds 6,751,103 common shares. Additionally, 258 common shares are held indirectly in the Alynne Starks 2012 Irrevocable Trust, for which Mr. Starks is the sole trustee.
In other recent news, Abbott Laboratories reported its first-quarter financial results, which showed a 1% increase in worldwide sales, aligning with consensus expectations. However, the company faced challenges in its diabetes and respiratory segments, with revenue missing expectations on an organic growth basis. Despite this, Abbott’s adjusted earnings per share slightly exceeded Wall Street estimates by $0.01. Several analyst firms have responded to these results by adjusting their price targets for Abbott. Leerink Partners lowered its target to $106, citing mixed results, while maintaining a Market Perform rating. Bernstein SocGen Group decreased its target to $110, noting an organic growth rate of about 3.0% in the first quarter. Piper Sandler also reduced its price target to $115, highlighting weak diabetes sales, yet kept an Overweight rating. TD Cowen adjusted its target to $115, pointing to lowered organic guidance and weaknesses in specific product lines. Additionally, Abbott received FDA clearance and CE Mark for its Ultreon 3.0 Software, an AI-powered coronary imaging platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.